Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Acute Hepatitis C Virus Infection Treated With Daclatasvir/Sofosbuvir in a 9-Year-Old Boy Publisher



Rahmani P1 ; Farahmand F2 ; Heidari G3
Authors

Source: Journal of Child Science Published:2022


Abstract

The present study includes a case report of a 9-year-old boy who came to our center with jaundice, elevated liver enzymes, and palpable liver. He was treated with ursodeoxycholic acid, but no improvement in symptoms was seen. Reverse transcription polymerase chain reaction and liver biopsy were positive for hepatitis C virus. He was treated with daclatasvir/sofosbuvir for 3 months. Daclatasvir/sofosbuvir might be effective against the treatment of hepatitis in children, with no report of remission and minimal side effects. © 2022. The Author(s).
Related Docs
View other Related Docs
1. Clinical Guideline and Diagnostic Algorithm of Acute Hepatitis With Unknown Origin in Children: Tehran Children’S Medical Center Protocol, Iranian Journal of Pediatrics (2023)
2. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline, Hepatitis Monthly (2016)
3. Evaluation of Acute Severe Hepatitis of Unknown Origin in Three Children in Iran: A Case Series, Iranian Journal of Pediatrics (2022)
Experts (# of related papers)
View all Related Experts
Reza Malekzadeh (7)
Hossein Poustchi (6)
Other Related Docs
4. The Combination of Sofosbuvir and Daclatasvir Is Effective and Safe in Treating Patients With Hepatitis C and Severe Renal Impairment, Journal of Gastroenterology and Hepatology (Australia) (2020)
5. Hepatitis A: Viral Structure, Classification, Life Cycle, Clinical Symptoms, Diagnosis Error, and Vaccination, Canadian Journal of Infectious Diseases and Medical Microbiology (2023)
6. Efficacy of Locally Manufactured Sofosbuvir and Daclatasvir (Sovodak) in Combination With Ribavirin in Treating Patients With Chronic Hepatitis C and Cirrhosis in Iran - Preliminary Report, Govaresh (2016)
7. Changes in Liver Fibrosis in Patients With Chronic Hepatitis C After Successful Direct-Acting Antiviral Therapy, International Journal of Clinical Practice (2021)
8. The Efficacy of 12Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients With Cirrhosis, Genotypes 1 and 3, Hepatitis Monthly (2017)
9. A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019, New Microbes and New Infections (2021)
10. Fulminant Hepatic Failure: A Rare and Devastating Manifestation of Coronavirus Disease 2019 in an 11-Year-Old Boy, Archives de Pediatrie (2020)
11. Efficacy of Direct Acting Antivirals (Daa) Therapy in Patients With Recurrent Hepatitis C After Liver and Kidney Transplantation: A Cross-Sectional Study, Frontiers in Medicine (2024)
12. Historical Epidemiology of Hepatitis C Virus (Hcv) in Select Countries - Volume 3, Journal of Viral Hepatitis (2015)
13. Covid-19 Infection and Liver Injury: Clinical Features, Biomarkers, Potential Mechanisms, Treatment, and Management Challenges, World Journal of Clinical Cases (2021)
14. An Intervention to Increase Hepatitis C Virus Diagnosis and Treatment Uptake Among People in Custody in Iran, International Journal of Drug Policy (2021)
15. Coronavirus Disease 2019 (Covid-19) in Children: Prevalence, Diagnosis, Clinical Symptoms, and Treatment, International Journal of General Medicine (2020)
16. Prevalence of Hepatitis C Infection in Iranian Hemodialysis Patients: An Updated Systematic Review and Meta-Analysis, Journal of Research in Medical Sciences (2017)
17. Update on the Prevalence of Hepatitis C Virus Infection Among Iranian General Population: A Systematic Review and Meta-Analysis, Hepatitis Monthly (2017)
18. Trends in Epidemiology of Hepatitis B and C Infections in Ilam Province: National Notifiable Diseases Surveillance System Data, Caspian Journal of Internal Medicine (2018)
19. Burden of Liver Diseases: A Review From Iran, Middle East Journal of Digestive Diseases (2019)
20. The Impact of Sofosbuvir/Daclatasvir or Ribavirin in Patients With Severe Covid-19, Journal of Antimicrobial Chemotherapy (2020)